Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 22, 2010

View Archived Issues

Spiroindolone NITD-609 protective against malaria in rodents

Preliminary phase I data on fully human anti-PNAG mAb F-598 disclosed

Palau Pharma identifies new histamine H4 receptor antagonists

Galapagos develops new phosphodiesterase 1A inhibitors for osteoarthritis

Phase III data presented on bisoprolol vs. carvedilol in elderly subjects with CHF

Peretinoin shows potential as first-line agent to prevent recurrence of HCC

Researchers discover differential miRNA expression in cervical cancer lesions

Hokkaido University and Shionogi claim new nucleoside-type antibiotics

Aquapharm and Dundee University to codevelop marine compounds for AD

FibroGen receives Chinese approval to begin clinical trials of FG-4592 in CKD anemia

FDA recommends approval of dabigatran etexilate for stroke prevention in AF

New S1P5 receptor agonists and antagonists described by Abbott

Pronova Biopharma and Abbott amend agreement for Omacor

Nippon Shinyaku launches Tramal in Japan for cancer pain

Epitomics and Michael J. Fox Foundation collaborate on LRRK2 antibodies

Clinical testing starts for ImmunoGen's anticancer therapy SAR-566658

CE mark approval for Promus Element stent in patients with diabetes and AMI

Enrollment begins in phase II trial of CYT-107 in chronic HIV infection

Takeda identifies new GPR119 receptor agonists

Pharmalucia claims new agents for bacterial and mycobacterial infections

NeuroSearch reports data from safety extension to phase III Huntexil trial

Data reported from extension study of Qnexa in obesity

Optimer submits rolling NDA for fidaxomicin in C. difficile infection

Tekmira to settle debts with Hana Biosciences

Signum Biosciences receives NIH grants for skin disorders

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...